• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

自体骨髓移植后大剂量卡铂及方案相关毒性

High-dose carboplatin and regimen-related toxicity following autologous bone marrow transplant.

作者信息

Colby C, Koziol S, McAfee S L, Yeap B, Spitzer T R

机构信息

Bone Marrow Transplantation Program/Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.

出版信息

Bone Marrow Transplant. 2002 Mar;29(6):467-72. doi: 10.1038/sj.bmt.1703417.

DOI:10.1038/sj.bmt.1703417
PMID:11960264
Abstract

Pharmacokinetic analysis of carboplatin dosing suggests a more accurate prediction of toxicity when the dose is based on the area under the plasma concentration vs time curve (AUC) instead of body surface area (BSA). We retrospectively calculated the carboplatin AUC of 117 patients who received an autologous stem cell transplant following a conditioning regimen consisting of carboplatin 1800 mg/m(2) and cyclophosphamide 6000 mg/m(2) to identify whether higher carboplatin exposure resulted in an increase in regimen-related non-hematologic toxicities. The most common non-hematologic toxicities were gastrointestinal and hepatic. Twenty (17%) patients experienced additional > or =grade 2 toxicity, specifically, renal toxicity significantly associated with a higher median AUC of 10.2 mg/ml(-1) min (P = 0.001). Prior platinum therapy was also significantly associated with toxicity (P = 0.052). While carboplatin dose based on BSA varied minimally (median 990 (range 450-1340) mg, the calculated AUC showed a near four-fold range of exposure (median 7.8 (range 3.6 to 13.8) mg/ml(-1) min). These data suggest a relationship between non-hematologic adverse events and the estimated AUC. Prospective trials will be necessary to identify the target carboplatin AUC which optimizes outcome and minimizes toxicity in the autologous transplant setting.

摘要

卡铂给药的药代动力学分析表明,当剂量基于血浆浓度-时间曲线下面积(AUC)而非体表面积(BSA)时,对毒性的预测更准确。我们回顾性计算了117例接受自体干细胞移植患者的卡铂AUC,这些患者在预处理方案中接受了1800mg/m²卡铂和6000mg/m²环磷酰胺,以确定更高的卡铂暴露量是否会导致与方案相关的非血液学毒性增加。最常见的非血液学毒性是胃肠道和肝脏毒性。20例(17%)患者出现额外的≥2级毒性,具体而言,肾毒性与更高的中位AUC 10.2mg/ml⁻¹min显著相关(P = 0.001)。既往铂类治疗也与毒性显著相关(P = 0.052)。虽然基于BSA的卡铂剂量变化最小(中位值990(范围450 - 1340)mg),但计算出的AUC显示暴露范围接近四倍(中位值7.8(范围3.6至13.8)mg/ml⁻¹min)。这些数据表明非血液学不良事件与估计的AUC之间存在关联。有必要进行前瞻性试验,以确定在自体移植环境中优化结局并使毒性最小化的目标卡铂AUC。

相似文献

1
High-dose carboplatin and regimen-related toxicity following autologous bone marrow transplant.自体骨髓移植后大剂量卡铂及方案相关毒性
Bone Marrow Transplant. 2002 Mar;29(6):467-72. doi: 10.1038/sj.bmt.1703417.
2
Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.120小时输注方案后卡铂的剂量个体化:更高的剂量强度但毒性更低。
Ther Drug Monit. 2006 Apr;28(2):212-8. doi: 10.1097/01.ftd.0000198646.32128.ef.
3
A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.一项I期试验,确定拓扑替康联合卡铂和依托泊苷在广泛期小细胞肺癌中的最大耐受全身暴露量。
Cancer Invest. 2005;23(6):511-9. doi: 10.1080/07357900500201400.
4
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.复发侵袭性淋巴瘤的治疗:含与不含高剂量治疗及干细胞救援的方案
Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12.
5
Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.卡铂与洛布拉地米尔联合应用于小儿脑肿瘤患者的药代动力学。
Cancer Chemother Pharmacol. 2004 Sep;54(3):206-12. doi: 10.1007/s00280-004-0791-4. Epub 2004 May 19.
6
Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma.用于神经母细胞瘤自体骨髓移植的含卡铂预处理方案后出现严重耳毒性。
Bone Marrow Transplant. 1998 Oct;22(7):669-74. doi: 10.1038/sj.bmt.1701391.
7
Future directions with carboplatin: can therapeutic monitoring, high-dose administration, and hematologic support with growth factors expand the spectrum compared with cisplatin?
Semin Oncol. 1992 Feb;19(1 Suppl 2):155-63.
8
A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.培美曲塞、卡铂及同步放疗用于局部晚期或转移性非小细胞肺癌或食管癌患者的I期研究。
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):515-22. doi: 10.1158/1078-0432.CCR-06-1058.
9
Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.每周一次紫杉醇、每周一次卡铂及同步放疗用于原发性宫颈癌的I期临床试验。
Gynecol Oncol. 2005 Jan;96(1):168-72. doi: 10.1016/j.ygyno.2004.09.009.
10
Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.接受高剂量卡铂治疗实体瘤的儿童中的适应性给药与铂-DNA加合物形成
Br J Cancer. 2007 Mar 12;96(5):725-31. doi: 10.1038/sj.bjc.6603607. Epub 2007 Feb 13.

引用本文的文献

1
Weekly vs Every-3-Week Carboplatin with Weekly Paclitaxel in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Analysis.三阴性乳腺癌新辅助化疗中每周一次卡铂与每三周一次卡铂联合每周一次紫杉醇的对比:一项回顾性分析
Breast Cancer (Dove Med Press). 2022 Mar 15;14:63-70. doi: 10.2147/BCTT.S342635. eCollection 2022.
2
The Xpc gene markedly affects cell survival in mouse bone marrow.Xpc基因显著影响小鼠骨髓中的细胞存活。
Mutagenesis. 2009 Jul;24(4):309-16. doi: 10.1093/mutage/gep011. Epub 2009 Apr 16.